Zusammenfassung
Fragestellung: Die elektive radikale Operation der regionären Lymphknoten (LK) gehört seit mehr als einem Jahrhundert zum Standard der Tumorchirurgie bei Karzinomen. Ob dieser Standard noch zeitgemäß ist, wird diskutiert. Methodik: Die Diskussion wird durch bekannte, randomisierte Studien und Kohortenstudien sowie durch Ergebnisse des Tumorregisters München vorbereitet. Ergebnis: Unter Metastasierung (MET) wird ein Tumorwachstum verstanden, das extravasal entsteht und auf migrierte Tumorzellen des Primärherdes zurückzuführen ist. Damit gibt es 3 Formen von MET. Bei regionären LK-MET reicht die Behandlung von der radikalen operativen und adjuvanten Therapie bis zum Watchful Waiting. Obwohl die Anzahl positiver LK bei allen Karzinomen einer der wichtigsten Prognosefaktoren ist, hat die Art der Behandlung der LK keinen Einfluss auf das Langzeitüberleben. Die Anzahl positiver LK ist demnach Indikator, aber nicht Ursache für die Fernmetastasierung. Dies scheint allgemeingültig zu sein. Auch ein Teil der Lokalrezidive kann als Folge einer lokalen MET in Betracht kommen. Ihre Häufigkeit kann durch operative, adjuvante systemische und strahlentherapeutische Maßnahmen stark variieren, wirkt sich aber ebenfalls nicht auf das Überleben aus. Distante MET bestimmen in der Regel den Krankheitsverlauf. Ob hämatogene MET die Quelle neuer, klinisch relevanter, die Prognose beeinflussender Absiedelungen sind, ist aufgrund des statistisch erfassten zeitlichen Auftretens infrage zu stellen. Schlussfolgerung: Die genetische Steuerung der MET legt einen prinzipiell gleichartigen MET-Prozess für alle Karzinome nahe. Die Hypothese „Metastasen metastasieren nicht“ hat aufgrund epidemiologischer Daten eine hohe Plausibilität: Eine Reduktion der elektiven Lymphknoten-Dissektionen (LKD) auf das für prognoseadaptierte Therapieentscheidungen erforderliche Ausmaß wäre dann (bio)-logisch konsequent.
Abstract
Purpose: Since more than a century elective radical dissection of regional lymph nodes is a standard procedure in tumour surgery. We discuss whether or not this standard is still up to date. Methods: The discussion was based on evaluations from well known clinical trials and cohort studies as well as from the results of the Munich Cancer Registry (MCR). Results: Distant metastases develop extravasally from disseminated tumour cells that originate from the primary tumour. Therefore, three categories of metastases can be described: First, regional lymph node metastases treated by surgical and/or adjuvant therapy or by watchful waiting. Although the number of positive lymph nodes is one of the most important prognostic factor in all cancer sites, treatment of lymph nodes does not affect long-term survival. The number of positive lymph nodes is therefore simply a marker, but not a cause, of distant metastases. This seems to be generally valid. Also, the major part of local recurrences can be seen as “local metastases”. The frequency of local relapse can be influenced by surgery, adjuvant treatment or radiotherapy only with a small impact on survival. Distant metastases normally determine the course of disease. Whether metastases can be a source of new clinically relevant metastases that influence the prognosis has to be questioned by the presented analyses of tumour growth times. Conclusions: The gene-based control of metastases implies a principal process of metastatic spread for solid tumours. The hypothesis “metastases do not metastasise” has a high plausibility. Reduction of lymph node dissection and its performance only in those cases where it is necessary for treatment decisions seems to be (bio)-logically consequent.
Schlüsselwörter
Lymphknotendissektion - Karzinomchirurgie - Metastasierung
Key words
lymph node dissection - cancer surgery - metastatic spread
Literatur
1
Bernards R, Weinberg R A.
A progression puzzle.
Nature.
2002;
418
823
2
Bonenkamp J J, Hermans J, Sasko M et al.
Extended lymph-node dissection for gastric cancer.
N Engl J Med.
1999;
340
908-914
3
Bruch H P, Schwandner O, Schiedeck T HK et al.
Actual standards and controversies on operative technique and lymph-node dissection in colorectal cancer.
Langenbeck's Arch Surg.
1999;
384
167-175
4
Bui L, Rempel E, Reeson D et al.
Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study.
J Surg Oncol.
2006;
93
439-445
5
Chambers A F, Groom A C, MacDonald I C.
Dissemination and growth of cancer cells in metastatic sites.
Nature Rev Cancer.
2002;
2
563
6
Chen S L, Bilchik A J.
More extensive nodal dissection improves survival for stages I to III of colon cancer – A population-based study.
Ann Surg.
2006;
244
602-610
7
Crile G.
Excision of cancer of the head and neck.
JAMA.
1906;
47
1780
8
DiMarco D S, Zincke H, Sebo T J et al.
The extent of lymphadenectomy for pTXN0 prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
J Urol.
2005;
173
1121-1125
9
Early Breast Cancer Trialists' Collaborative Group .
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
Lancet.
2005;
366
2087-2106
10
Eccles S A, Welch D R.
Metastasis: recent discoveries and novel treatment strategies.
Lancet.
2007;
369
1742-1757
11
Engel J, Lebeau A, Sauer H et al.
Are we wasting our time with the sentinel technique? Fifteen reasons to stop axilla dissection.
The Breast.
2006;
15
452
12
Engel J, Hölzel D.
Signal für einen Paradigmawechsel.
Dtsch Ärztebl.
2001;
98
A2365
, (Leserbrief zum „Konzept des Wächterlymphknotens“)
13
Engel J, Eckel R, Kerr J et al.
The process of metastasisation for breast cancer.
Eur J Cancer.
2003;
39
1794-1806
14
Feinstein A R, Sosin D M, Wells C K.
The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.
N Engl J Med.
1985;
312
1604-1608
15
Ferlito A, Johnson J T, Rinaldo A et al.
European surgeons were the first to perform neck dissection.
Laryngoscope.
2007;
117
797-802
16
Ferlito A, Rinaldo A.
Errare humanum est, in errore perseverare stultum: this is true also for neck dissection.
Oral Oncology.
2005;
41
132-134
17
Fidler I J.
The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited.
Nature Rev Cancer.
2003;
3
1
18
Fisher B, Jeong J H, Anderson S et al.
Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.
N Engl J Med.
2002;
347
567
19
Fisher B, Anderson S, Bryant J et al.
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.
N Engl J Med.
2002;
347
1233-1241
20
Gatta G, Capocaccia R, Sant M et al.
Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study.
Gut.
2000;
47
533-538
21
Gervasoni J E, Sbayi S, Cady B.
Role of lymphadenectomy in surgical treatment of solid tumors: An update on the clinical data.
Ann Surg Oncol.
2007;
14
2443-2462
22
Halsted W.
The results of operations for the cure of the cancer of the breast performed at the Johns Hopkins Hospital from June 1889 to January 1894.
Arch Surg.
1894;
20
497
23
Hanahan D, Weinberg R A.
The hallmarks of cancer cell.
Cell.
2000;
100
57
24
Hartgrink H H, van de Velde C JH, Putter H et al.
Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomised Dutch Gastric Cancer Group Trial.
J Clin Oncol.
2004;
22
2069-2077
25
Hirakawa S, Brown L F, Kodama S et al.
VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites.
Blood.
2007;
109
1010-1017
26
Hohenberger W, Merkel S, Weber K.
Lymphadenektomie bei Tumoren des unteren Gastrointestinaltraktes.
Chirurg.
2007;
78
217-225
27
International Breast Cancer Study Group .
Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: First results of International Breast Cancer Study Group Trial 10–93.
J Clin Oncol.
2006;
24
337-344
28
Kang Y, Siegel P M, Shu W et al.
A multigenic program mediating breast cancer metastasis to bone.
Cancer Cell.
2003;
3
537
29
Klein C A, Hölzel D.
Systemic cancer progression and tumor dormancy.
Cell Cycle.
2006;
5
1788-1798
30
Lähdesmäki H, Hao X, Sun B et al.
Distinguishing key biological pathways between primary breast cancers and their lymph node metastases by gene function-based clustering analysis.
Int J Oncol.
2004;
24
1589-1596
31
Liu R, Wang X, Chen G Y et al.
The prognostic role of a gene signature from tumorigenic breast-cancer cells.
N Engl J Med.
2007;
356
217-226
32
Minn A J, Gupta G P, Siegel P M et al.
Genes that mediate breast cancer metastasis to lung.
Nature.
2005;
436
518
33
Morton D L, Thompson J F, Cochran A J et al.
Sentinel-node biopsy or nodal observation in melanoma.
N Engl J Med.
2006;
355
1307
34
Neuhaus S J, Clark M A, Thomas J M.
Dr. Herbert Lumley Snow, MRCS (1847–1930): the original champion of elective lymph node dissection in melanoma.
Annals Surg Oncol.
2004;
11
875-878
35
Pachmann K, Clement J H, Schneider C P et al.
Standardized quantification of circulating peripheral tumor cells from lung and breast cancer.
Clin Chem Lab Med.
2005;
43
617-627
36
Pack G T, Scharnagel I M, Morfit M.
The principle of excision and dissection in continuity for primary and metastatic melanoma of the skin.
Surgery.
1945;
17
849
37
Rouffet F, Hay J M, Vacher B et al.
Curative resection for left colonic carcinoma: Hemicolectomy vs. segmentel colectomy.
Dis Colon Rectum.
1994;
37
651
38
Sauer R, Becker H, Hohenberger W et al.
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
N Engl J Med.
2004;
351
1731
39
Schröder F, Kurth K H, Fossa S D et al.
Early versus delayed endocrine treatment of pN1–3M0 prostate cancer without local treatment of the primary tumor: result of the EORTC trial 30846 – a phase III study.
J Urol.
2004;
172
923-927
40 Siewert J R, Rothmund M, Schumpelick V Hrsg. Praxis der Viszeralchirurgie: Onkologische Chirurgie. 2. Aufl. Heidelberg: Springer; 2006
41
Siewert J R.
Lymphadenektomie – Ein Glaubensbekenntnis?.
Chirurg.
2007;
78
181
42
Sugarbaker E V, Cohen A M, Ketcham A S.
Do metastases metastasize?.
Annals Surg.
1971;
174
161-166
43
Tait C R, Dodwell D, Horgan K.
Do metastases metastasize?.
J Pathol.
2004;
203
515-518
44 Tumorregister München . http://www.tumorregister-muenchen.de/facts/specific_analysis.html; Stand: 19.11.2008
45
Van de Vijver M J, He Y D, van't Veer L J et al.
A gene expression signature as a predictor of survival in breast cancer.
N Engl J Med.
2002;
347
1999
46
Veronesi U, Marubini E, Mariani L et al.
The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial.
Eur J Cancer.
1999;
35
1320
47
Wang Y, Klijn J GM, Zhang Y et al.
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
Lancet.
2005;
365
679
48 Weinberg R A Hrsg. The Biology of Cancer. New York: Garland Science; 2007 (Chapter 14)
49
Weyers W.
Excision of melanoma in historical perspective: Triumph of irrationality for nearly a century.
History.
1997;
3
238
50
Wong S L, Hong J M, Hollenbeck B K et al.
Hospital lymph node examination rates and survival after resection for colon cancer.
JAMA.
2007;
298
2149-2154
Prof. Dr. D. Hölzel
IBE / Klinikum Großhadern
Marchioninistr. 15
81377 München
Email: hoe@ibe.med.uni-muenchen.de